Q2 2026 Bionano Genomics Inc Earnings Call Transcript
Key Points
- Record Q2 2026 flow cell sales of 9,219 units, up 27% year-over-year, driven by increased clinical adoption.
- Consumable revenue grew 30% year-over-year to $4.3 million, reflecting higher recurring revenue mix.
- Adjusted gross margin reached a record 53% in Q2 2026, up from 52% in Q2 2025, due to operational efficiencies.
- Fully retired senior secured convertible debt in Q2 2026, simplifying the balance sheet.
- Raised the low end of full-year 2026 revenue guidance to $31-$33 million, reflecting confidence in growth.
- Flow cell supply constraints persist, with demand outpacing manufacturing capacity, limiting near-term revenue growth.
- Software revenue declined 16% year-over-year to $1.4 million due to customer deployment delays.
- Q3 2026 revenue guidance of $8.2-$8.6 million implies potential flat to modest sequential growth, with risk of large order timing.
- Cash position remains low at $10.4 million, with runway only into Q1 2027, raising liquidity concerns.
- Reimbursement for constitutional genetic disorders remains at a lower level than hematologic malignancies, with no progress on improvement.
Good day, and welcome to the Bionano second-quarter 2026 earnings conference call. Today's conference is being recorded.
At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.
Thank you, Operator, and good afternoon, everyone. Welcome to the Bionano second-quarter 2026 financial results conference call. On the call today are Dr. Al Luderer, Chairman and Interim CEO of Bionano, and Mark Adamchak, Bionano's Vice President of Accounting and Principal Accounting Officer. After market closed today, Bionano issued a press release announcing its financial results for the second-quarter of 2026. A copy of the release can be found on the Investor Relations page of the company's website.
Certain statements made during this conference call may be forward-looking statements. Actual results may differ materially from such statements due to several factors and risks, some of which are identified in Bionano's press release and Bionano's report filed with the SEC
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
